Millions of Americans take Ozempic, Wegovy, and other GLP-1 medications to manage diabetes or lose weight. Now, the U.S. Food and Drug Administration (FDA) is requiring new warnings about a rare but potentially permanent form of vision loss associated with these drugs.
On November 9, 2026, the FDA announced new safety labeling requirements for GLP-1 medications, citing evidence of a possible increased risk of non-arteritic anterior ischemic optic neuropathy (NAION).
The announcement comes as around 150 plaintiffs in the Ozempic vision loss MDL allege that drugmakers failed to adequately warn them about vision injuries.
What matters to the everyday Americans currently taking GLP-1 medications and those who have already suffered vision loss is how the FDA label change order could affect them.
FDA Requires New Vision Loss Warnings for GLP-1 Drugs
The FDA is requiring manufacturers to add information about NAION to the Warnings and Precautions section of labels for all GLP-1 receptor agonists. The order extends beyond Novo Nordisk's Ozempic and Wegovy; other medications that must update their warning label include Rybelsus, Mounjaro, Zepbound, Trulicity, Victoza, and Saxenda.
NAION occurs when blood flow to the optic nerve is reduced, causing sudden, usually painless vision loss, typically in one eye. Sometimes called an "eye stroke," the condition can cause permanent damage.
The FDA's announcement follows several studies examining a possible connection between GLP-1 drugs and NAION, including 2024 research published in JAMA Ophthalmology. Such research has caused the Ozempic vision loss MDL to expand significantly from the 29 lawsuits initially consolidated in December 2025.
While the agency said there is a potential increased risk, it hasn’t established that GLP-1 medications directly cause NAION.
How Common is Vision Loss Among GLP-1 Users?
NAION remains rare, but the FDA's findings suggest patients taking GLP-1 medications may face an increased risk.
The agency analyzed 126 randomized clinical trials involving more than 134,000 participants. Researchers identified:
· 6.4 NAION cases per 100,000 person-years among GLP-1 users.
· 3.8 cases per 100,000 person-years among patients receiving comparison treatments.
"Person-years" is a way researchers measure risk by accounting for both the number of people studied and how long they were followed. For example, 100,000 person-years could represent 100,000 people followed for one year or 50,000 people followed for two years.
The key takeaway is that the research translates to approximately 2.6 additional cases of NAION for every 100,000 people treated for one year.
The FDA also examined real-world medical data. GLP-1 users had a statistically significant increased risk compared with patients taking one class of diabetes medications, but not another.
Other research has produced similar concerns involving semaglutide, the name for GLP-1 drugs. A 2026 study involving U.S. veterans found semaglutide users had more than twice the risk of NAION compared with patients starting another diabetes medication, although the absolute risk remained low.
The findings are concerning, but researchers still don't fully understand how GLP-1 medications might contribute to optic nerve damage. Diabetes, high blood pressure, and other conditions can independently increase NAION risk.
What Does the FDA Warning Mean for Ozempic Vision Loss Lawsuits?
The FDA's decision could become important evidence in ongoing GLP-1 vision loss litigation, although it doesn't automatically establish that manufacturers are legally responsible for patients' injuries.
Currently, at least 150 patients have filed lawsuits alleging Wegovy and Ozempic caused NAION and permanent vision loss. Plaintiffs claim that drugmakers failed to adequately warn patients and physicians about potential vision injuries.
The FDA's new labeling requirement gives current and future plaintiffs an additional regulatory development to point to, but several legal questions remain:
- When did manufacturers know, or when should they have known, about the potential vision loss risk?
- Were earlier warnings adequate based on the scientific evidence available at the time?
- Can individual patients establish that a GLP-1 medication caused their vision loss?
The timing of the FDA's warning, the available scientific evidence, and applicable state law could influence individual Ozempic vision lossclaims.
Importantly, federal approval of a warning doesn’t automatically prove a manufacturer was negligent or that an earlier warning was legally inadequate.
What If You Developed NAION Before the FDA Warning?
For patients taking Ozempic and other GLP-1 drugs and developed vision loss before the FDA ordered NAION be added to warning labels, whether it strengthens their lawsuit is unclear right now.
Some may assume the FDA’s announcement confirms their injury was caused by GLP-1 medication. But it’s complicated because a warning issued today doesn't necessarily prove a manufacturer should have provided the same warning years earlier.
In failure to warn lawsuits, courts may examine:
- The scientific evidence available when a patient received the medication
- What manufacturers knew about possible risks
- What information physicians and patients were given
For Ozempic vision loss plaintiffs, other factors like medical records, prescription history, the timing of symptoms, and an ophthalmologist's diagnosis, may all become important evidence.
Patients should also understand that not every vision problem associated with diabetes or GLP-1 treatment is NAION. An accurate diagnosis matters medically and legally.
Should Patients Stop Taking Ozempic or Other GLP-1 Drugs?
The FDA is not recommending that everyone discontinue GLP-1 medications.
These drugs provide important benefits for many patients, including blood sugar management and weight reduction. Stopping treatment without medical guidance can create additional health risks.
However, patients should recognize the warning signs of NAION, including sudden painless vision loss, blurred or missing areas of vision, changes in color perception, or reduced central vision.
If you’re taking a GLP-1 medication and experience sudden vision loss, don’t wait for a routine appointment.
The FDA advises patients who have experienced eye problems to discuss whether they should continue or stop using their GLP-1 medication with their healthcare professional. Patients can also report suspected medication-related injuries FDA MedWatch.
What the New FDA Warning Means for Ozempic Users
The FDA's decision to require drug manufacturers to add the risk of NAION to warning labels marks an important development in understanding the potential risks of GLP-1 medications.
It also adds another dimension to the growing litigation involving these diabetes weight loss drugs. Over 4,000 cases are in the GLP-1 gastrointestinal MDL, and there was even an Ozempic wrongful death claim filed in March.
For patients, the new warning reinforces the importance of understanding possible side effects, reporting vision changes promptly, and discussing risk factors with their healthcare providers.
For those who have already experienced NAION, the announcement may raise new questions about the warnings they received and their potential legal options.
At the end of the day, determining what the new vision loss warning for GLP-1 medications means for individual injuries and lawsuits will require further medical and legal examination.
